Cannabis and Eating Disorders

Not medical advice

This article summarizes published research. It is not medical advice and is not a substitute for evaluation and treatment by a qualified clinician. Eating disorders have among the highest mortality rates of any psychiatric illness. If you or someone you know is struggling, contact a physician, a specialist eating disorder service, or a crisis line. Do not use cannabis as a substitute for evidence-based treatment.

Plain-language summary

Eating disorders include anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), and avoidant/restrictive food intake disorder (ARFID), among others. The endocannabinoid system helps regulate appetite, reward, and body weight, so cannabinoids are a reasonable thing to study in these conditions ^[1][2].

Despite this biological plausibility and despite cannabis's well-known appetite-stimulating effect, the clinical evidence base is small. The single best study is a 2014 randomized trial of dronabinol (synthetic THC) in women with severe, chronic anorexia nervosa, which found a small but statistically significant weight gain over four weeks with no measurable effect on eating-disorder psychopathology ^[3] Weak / limited. There are no positive controlled trials for bulimia, binge eating, or ARFID No data.

Meanwhile, observational studies link cannabis use in people with eating disorders to higher rates of substance use disorders, impulsivity, and in some cohorts worse clinical course ^[4][5].

What probably works

Nothing, at the level of 'probably works,' has been established for eating disorders specifically. No cannabinoid product is approved by the FDA, EMA, or MHRA for any eating disorder indication.

The closest evidence is in related but distinct conditions:

• Dronabinol for anorexia associated with AIDS wasting is FDA-approved and increases appetite and weight, based on trials from the 1990s ^[6] Strong evidence.
• Cannabinoids for chemotherapy-induced nausea and vomiting have moderate evidence, per systematic reviews ^[7] Strong evidence.

These should not be extrapolated to primary eating disorders, where the problem is not a missing appetite signal but a complex psychiatric syndrome involving body image, control, reward, and often trauma.

What might work

Dronabinol in chronic anorexia nervosa. Andries et al. (2014) randomized 24 women with severe, enduring AN (mean illness duration ~17 years) to dronabinol 2.5 mg twice daily versus placebo for four weeks in a crossover design. Dronabinol produced a mean weight gain of about 0.73 kg over placebo. Eating-disorder psychopathology scores did not improve ^[3] Weak / limited. The trial was small, short, and in a highly chronic population, so results should not be generalized to adolescents or acute-onset AN.

Endocannabinoid system as a target. Human imaging studies show altered CB1 receptor availability in patients with AN and BN compared with healthy controls, suggesting endocannabinoid tone is disrupted in these disorders ^[2][8] Weak / limited. This is a mechanistic finding, not a treatment.

CBD for anxiety comorbidity. Anxiety disorders are common in ED populations, and there is preliminary human evidence for CBD in some anxiety conditions ^[9] Weak / limited. Whether treating comorbid anxiety with CBD improves ED outcomes has not been tested No data.

What doesn't work, or has weak/negative evidence

• Recreational cannabis as self-treatment for AN. No controlled evidence supports it. Observational studies of people with AN who use cannabis do not show better outcomes and often show worse psychiatric comorbidity ^[4][5] Weak / limited.
• Cannabis for bulimia nervosa. No RCTs. Mechanistically, THC's disinhibiting effect on eating could plausibly worsen binge–purge cycles, though this has not been formally tested No data.
• Cannabis for binge eating disorder. No RCTs. Cannabis use is associated with increased caloric intake and, in some studies, higher BMI over time in heavy users ^[10]; using an appetite-stimulating drug to treat a binge disorder is not a sound premise No data.
• The claim that 'indica strains calm eating anxiety.' Folklore. Indica/sativa labels do not reliably predict clinical effects and are not a basis for treatment decisions Disputed.

What we don't know

• Whether dronabinol's small weight effect in chronic AN persists beyond four weeks, or generalizes to adolescents or acute AN.
• Whether CBD (non-intoxicating) has any role in ED-related anxiety, body-image distress, or OCD-like features.
• Whether cannabis use during ED recovery increases relapse risk in a causal way, or simply co-occurs with other risk factors.
• Whether targeting the endocannabinoid system pharmacologically (e.g., FAAH inhibitors, peripheral CB1 modulators) could help. This is active preclinical research with no human ED trials to date No data.
• Interactions between cannabis and standard ED medications (SSRIs, olanzapine) in this population.

Comparison with standard treatments

Evidence-based treatment for eating disorders looks nothing like a cannabinoid prescription:

• Anorexia nervosa: Nutritional rehabilitation and psychotherapy are the foundation. Family-Based Treatment (FBT) has the strongest evidence in adolescents. Olanzapine has modest evidence for weight restoration in adults ^[11] Strong evidence.
• Bulimia nervosa: Cognitive Behavioral Therapy for eating disorders (CBT-E) is first-line. Fluoxetine at 60 mg is the only FDA-approved medication ^[12] Strong evidence.
• Binge eating disorder: CBT-E and interpersonal therapy have strong evidence. Lisdexamfetamine is FDA-approved for moderate-to-severe BED ^[13] Strong evidence.

Against this backdrop, cannabis-based interventions are, at best, experimental adjuncts in narrowly defined subgroups (chronic, treatment-resistant AN), not replacements for standard care.

Risks specific to eating disorder populations

• Substance use comorbidity. People with eating disorders, especially the binge–purge subtype of AN and BN, have elevated rates of substance use disorders. Introducing regular cannabis use is a real risk in this group ^[4][5].
• Psychiatric effects. THC can worsen anxiety, paranoia, and depersonalization at higher doses. ED patients often already experience high anxiety and dissociation.
• Cognitive and motivational effects. Regular heavy use may impair executive function, which is already compromised in acute starvation states.
• Cardiovascular concerns. Severely underweight patients with AN often have bradycardia, hypotension, and QT abnormalities. THC's tachycardic effect is not benign in this context.
• Interference with treatment engagement. Regular cannabis use is associated with poorer adherence to psychotherapy in several psychiatric populations.

See also: Cannabis and Anxiety, Cannabis Use Disorder, Dronabinol.

Bottom line

Cannabis is not a treatment for eating disorders. One small trial supports a modest weight-gain effect from dronabinol in long-standing anorexia nervosa; that is the entire positive human evidence base. For bulimia, binge eating, and ARFID, there is essentially nothing. Standard care — psychotherapy, nutritional rehabilitation, and where indicated specific medications — remains the correct starting point. Anyone considering cannabinoids as part of ED management should do so only under specialist supervision.

Sources

How this page was made

Related

• Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...